drugset / Trial / NCT06111014
Continuation Study for Latozinemab
NaSingle-groupOpen-labelTreatment
Summary
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
Timeline
- Start
- 2023-12-08
- Primary completion
- 2025-09-01
- Completion
- 2026-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Latozinemab | Monoclonal antibody | 60 mg/kg | Intravenous |